About Tarus Therapeutics
Tarus Therapeutics is a Healthcare company based in New York (United States) founded in 2019 by Donald R Dye and Peter Molloy, and was acquired by Portage Biotech in July 2022. Cancer therapeutics targeting the adenosine pathway are developed. The company was acqui-hired. Tarus Therapeutics offers products and services including iNKT Platform, Adenosine Platform, and Other Programs. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Portage Biotech Inc.
Company details
Tarus Therapeutics was founded in 2019 in New York, United States. Therapeutics for cancer treatment are developed by the company within the biotechnology sector. Lead candidates are focused on the immunosuppressive adenosine pathway in the tumor microenvironment. These candidates are aimed at addressing resistant cancers through operations centered on drug development. The companys activities are based in the United States.
- Headquarters New York, United States
- Founders Donald R Dye, Peter Molloy
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website tarustx.com
- Social LinkedIn
- Acquired by Portage Biotech (Jul 2022)
- Legal Name Portage Biotech Inc.
- Investors
- Acquired byPortage Biotech
(Jul 2022)
Products & Services of Tarus Therapeutics
Tarus Therapeutics offers a comprehensive portfolio of products and services, including iNKT Platform, Adenosine Platform, and Other Programs.
Develops therapies targeting cancer resistance pathways
Focuses on immuno-oncology drug development for cancer
Advances additional novel assets in oncology research
Investors in Tarus Therapeutics
Tarus Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Portage Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics based on Cell Permeable Peptide Platform | 2013 | portagebiotech.com | Tortola, United Kingdom |
Investor details for Tarus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tarus Therapeutics
2 people are tracked at Tarus Therapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Donald R Dye | Co-Founder | Leadership |
Peter Molloy | Co-Founder | Leadership |
Complete people profiles for Tarus Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Tarus Therapeutics
2 dated milestones of Tarus Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Tarus Therapeutics is founded.
- Exit Acquired by Portage Biotech.
Top companies in Oncology
3 companies that operate in the same segment as Tarus Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tarus Therapeutics
Complete news archive for Tarus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tarus Therapeutics
Tarus Therapeutics was founded in 2019.
Tarus Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Tarus Therapeutics was founded in 2019 in New York, United States. Therapeutics for cancer treatment are developed by the company within the biotechnology sector. Lead candidates are focused on the immunosuppressive adenosine pathway in the tumor microenvironment. These candidates are aimed at addressing resistant cancers through operations centered on drug development. The companys activities are based in the United States.
Tarus Therapeutics offers iNKT Platform, Adenosine Platform, and Other Programs.
Tarus Therapeutics has 1 investor. Key investors include Portage Biotech.
Tarus Therapeutics operates through Portage Biotech Inc..
Yes. Tarus Therapeutics was acquired by Portage Biotech in July 2022.

